DF/HCC Program Affiliation

Breast Cancer

Research Abstract

My research interests include the integration of therapies for early breast cancer and the development of new, targeted therapies for both advanced and early breast cancer. In collaboration with colleagues in the Department of Radiation Therapy, I have investigated optimal strategies for combining chemotherapy and breast radiation in the management of primary breast breast cancer. Through a series of Harvard, industry-sponsored, and Cooperative Group trials, I am presently focussing on the development of new hormonal and biologic agents, cross-talk between endocrine and growth factor pathways, and presurgical models to better evaluate breast cancer biology. With members of the Department of Pathology, I am working to better define prognostic factors in early breast cancer.

Publications

• Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early bre
  17317830
• Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE.Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.Clin Breast Canc
  16800976
• Come SE.A 62-year-old woman with a new diagnosis of breast cancer.JAMA 2006 Mar 22;295(12):1434-42.
  16551716
• Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C.Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Thera
  16467115
• Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA.Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.Clin Pharmacokinet 2004;43(8):529-38.
  15170367
• Bellon JR, Shulman LN, Come SE, Li X, Gelman RS, Silver BJ, Harris JR, Recht A.A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma.Cancer 2004 Apr 1;100
  15042668
• Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS.Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocri
  14734487
• Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C.Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospectiv
  12872340
• Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS.Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of B
  12538498
• Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A.Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postme
  12177098
• Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR.The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.N Engl J Med 1996 May 23;334(21):1356-61.
  8614420